MBX Biosciences (MBX) Operating Leases (2023 - 2026)

MBX Biosciences has disclosed Operating Leases across 4 years of filings, most recently posting $377000.0 for Q1 2026.

• Operating Leases for Q1 2026 came in at $377000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $377000.0 (changed N/A YoY), and the FY2025 annual result was $424000.0, changed N/A from the prior year.
• Operating Leases came in at $377000.0 for Q1 2026 at MBX Biosciences, down from $424000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $512000.0 in Q2 2025 to a low of $44000.0 in Q3 2024.
• The 4-year median for Operating Leases is $400500.0 (2025), against an average of $332833.3.
• Peak annual rise in Operating Leases reached 965.91% in 2025, while the deepest fall reached 965.91% in 2025.
• MBX Biosciences' Operating Leases stood at $171000.0 in 2023, then tumbled by 74.27% to $44000.0 in 2024, then jumped by 863.64% to $424000.0 in 2025, then dropped by 11.08% to $377000.0 in 2026.
• The last three Operating Leases figures came in at $377000.0 (Q1 2026), $424000.0 (Q4 2025), and $469000.0 (Q3 2025), per Business Quant data.